

PATIENT DEMOGRAPHICS	Patient Name: Synth Urine	Account: SalvusLabs, LLC	Order Code: NE22-0007351 ()
	DOB: 06/05/2023	Provider: Physician No	Collected: 10/27/2023
	Patient Gender: U	Accession: 233549	Received: 10/27/2023
	Patient Phone Number: 6787381999	Report Status: AMENDED	Reported: 11/19/2023

PREScription	None	DIAGNOSIS
LIST		CODES

INCONSISTENT			
NOT PRESCRIBED			DETECTED
Class	Test	Cutoff (ng/mL)	Results (ng/mL)
DIURETIC	Furosemide	50	900.91
[DDI] (Efficacy) Metformin,Glipizide - (Excretion) Sitagliptin - (Hypotension) Duloxetine - (Other) The risk or severity of adverse effects can be increased when Furosemide is combined with Salicylic acid.			
ANTIDIABETIC	Metformin	500	> 25000
[DDI] (Other) Salicylic acid may increase the hypoglycemic activities of Metformin. The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Metformin.			
ANTIDIABETIC	Glipizide	10	38.64
[DDI] (Other) The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Glipizide. Sitagliptin may increase the hypoglycemic activities of Glipizide. Salicylic acid may increase the hypoglycemic activities of Glipizide.			
ANTIDIABETIC	Sitagliptin	50	> 2500
[DDI] (Excretion) Salicylic Acid - (Other) The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Sitagliptin.			
RECREATIONAL	Ethyl Glucuronide (Metabolite of Ethyl Alcohol)	500	552.81
Ethyl Sulfate must also be present for determination of alcohol consumption by drinking, additional clinical presentations should be considered.			
RECREATIONAL	Ethyl Sulfate (Metabolite of Ethyl Alcohol)	200	235.89
Ethyl Glucuronide must also be present for determination of alcohol consumption by drinking, additional clinical presentations should be considered.			
STIMULANT	Caffeine	500	1579.16
High values not necessarily of concern, additional clinical presentations should be considered			
ANTIDEPRESSANT	Duloxetine	50	194.35
[DDI] (Other) The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Salicylic acid.			
CARDIOVASCULAR	Rivaroxaban	50	1759.04
[DDI] (Excretion) Glipizide,Caffeine,Furosemide,Metformin - (Concentration - Increase) Sitagliptin - (Efficacy) Furosemide - (Other) The risk or severity of hemorrhage can be increased when Duloxetine is combined with Rivaroxaban. The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Rivaroxaban.			
NSAID	Salicylic Acid (Metabolite of Acetylsalicylic Acid)	400	1791.12

INCONSISTENT		
PRESCRIBED		NOT DETECTED
"NO RESULTS"		

VALIDITY TESTING & SCREENS		
Specimen Validity	Range	Results
PH	4.50 - 8.00	4.3
Specific Gravity	1.01 - 1.03	1.015
Urine Creatinine (mg/dL)	20.00 - 400.00	48.71

CONSISTENT	
PRESCRIBED	
DETECTED	
"NO RESULTS"	

PATIENT DEMOGRAPHICS	Patient Name: Synth Urine	Account: SalvusLabs, LLC	Order Code: NE22-0007351 ()
	DOB: 06/05/2023	Provider: Physician No	Collected: 10/27/2023
	Patient Gender: U	Accession: 233549	Received: 10/27/2023
	Patient Phone Number: 6787381999	Report Status: AMENDED	Reported: 11/19/2023

NOT PRESCRIBED				NOT DETECTED			
Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)
4-Hydroxydiclofenac	50	Clonazepam	20	Naproxen	100	Sufentanil	5
Diclofenac	50	Clonidine	50	N-Desmethylicitalopram	50	Sumatriptan	50
Dihydrocodeine	50	Codeine	50	N-Desmethylozapine	25	Tapentadol	50
Diltiazem	50	Cotinine	50	N-Desmethyloirtazapine	25	Temazepam	40
Fluoxetine	25	Cyclobenzaprine	50	N-Desmethyloanzapine	25	Topiramate	50
Gabapentin	1000	Dehydroaripiprazole	20	N-Desmethyltapentadol	50	Tramadol	100
Lisinopril	50	Desalkylflurazepam	40	Norbuprenorphine	30	Trazodone	50
Carboxybuprofen	400	Desipramine	50	Nordiazepam	40	Valsartan	50
Digoxin		Dextrorphan	25	Norfentanyl	8	Venlafaxine	100
7-Aminoclonazepam	40	Diazepam	10	Norhydrocodone	50	Warfarin	10
7-Aminoflunitrazepam	40	Diphenhydramine	50	Norketamine	10	Zaleplon	10
9-Hydroxyrisperidone	10	Donepezil	50	Normeperidine	100	Ziprasidone	25
Acetaminophen	400	Doxepin	30	Noroxycodone	50	Zolmitriptan	50
a-Hydroxymidazolam	30	EDDP	100	Norpropoxyphene	100		
a-Hydroxytriazolam	30	Fentanyl	2	Nortriptyline	50		
alpha-Hydroxyalprazolam	30	Glyburide	10	Norverapamil	50		
Alprazolam	30	Haloperidol	25	O-Desmethyltramadol	100		
Amitriptyline	50	Hydrochlorothiazide	50	O-Desmethylvenlafaxine	100		
Amlodipine	25	Hydrocodone	50	Olanzapine	25		
Amphetamine	200	Hydromorphone	50	Oxazepam	40		
Apixaban	25	Hydroxybupropion	50	Oxycodone	50		
Aripiprazole	20	Imipramine	50	Oxymorphone	50		
Atenolol	50	Indomethacin	50	Paroxetine	25		
Atomoxetine	50	Irbesartan	50	Phenobarbital	100		
Atorvastatin	10	Levetiracetam	50	Phentermine	100		
Baclofen	50	Lorazepam	40	Pioglitazone	50		
Buprenorphine	10	Lurasidone	25	Pitavastatin	10		
Buspirone	50	Meprobamate	200	Pregabalin	150		
Butalbital	100	Methadone	100	Propranolol	50		
Carbamazepine	50	Methotrexate	50	Protriptyline	50		
Carbamazepine Epoxide	50	Metoprolol	50	Pseudoephedrine	50		
Carboxyclopidogrel	50	Mitragynine	25	Quetiapine	50		
Carboxyzolpidem	50	Morphine	50	Risperidone	10		
Carisoprodol	19	Mycophenolic acid	50	Ritalinic Acid	50		
Celecoxib	50	Naloxone	10	Rosuvastatin	20		
Chlorpromazine	25	Naltrexone	10	Sertraline	50		

IMPORTANT DISCLAIMER NOTICE : Newstar warrants that all lab analysis provided is conducted professionally in accordance with all applicable standard laboratory practices and that this data reflects Newstar's attempt to generate accurate results for the specific sample(s) submitted to generate this report. Newstar has developed the tests used during the lab analysis and determined their performance characteristics. The tests have not been cleared or approved by the Food and Drug Administration. The results provided are based on information provided by the Customer. Report results are contingent on the accuracy of the prescription list, diagnosis codes, and government databases used to determine drug contraindications and drug interactions. This data reflects Newstar's attempt to generate accurate results based on the information that was provided to Newstar by the Customer and relying on the established government databases available to Newstar for the specific sample(s). Newstar disclaims any and all liability for any errors and is not responsible for any claims or damages related to the reliability of the test results.